RSS   Newsletter   Contact   Advertise with us
Post Online Media

Outcome Capital adds Ellen S. Baron to management team

Outcome CapitalOutcome Capital, a highly specialized investment banking firm, strengthened its leadership by adding Ellen S. Baron to its executive team.
Article continues below

READ MORE Zynerba names Richard Baron VP and CFO

A pharmaceutical and biotechnology veteran, Dr. Baron has more than 30 years of operational, strategic and investment expertise with an emphasis in oncology, neurology, and infectious disease.

Dr. Baron joins Outcome from Healthios Capital Markets, LLC, where she was Managing Director, Biopharmaceuticals.

Dr. Baron previously led numerous therapeutic and diagnostic investments as a Partner with Oxford Bioscience Partners, a healthcare venture capital firm.

Dr. Baron currently serves on the board of directors of several companies, including Sixth Element Capital, a UK-based oncology focused venture capital fund, and SFH, a Maine-based nutraceutical company.

Dr. Baron holds a Ph.D. in Microbiology from Georgetown University School of Medicine and a post-doctorate from New York’s Public Health Research Institute.



We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy